Another Success for BioDelivery Sciences & 175% in 8 Months for PropThink Readers
Insights - Since Mr. Deryugin suggested in December that BioDelivery Sciences (BDSI) would be delivering profits in 2014, this pick is up 175%.
Read NowzFree
The Weekly Biotech Roundup, Here are Our Latest Trades & Insights
Recap - It was a shortened trading week in the U.S. with markets closed the entirety of Friday and half of Thursday, though activity and volatility in the healthcare … Continue Reading
Read Now
Regado’s Safety Problem Only Compounds Another Issue: Its Capital Needs
Insights - Shares of Regado Biosciences (RGDO) fell 50% after the company reported an unplanned review of the ongoing REGULATE-PCI phase 3 trial of its novel anti-coagulant, Revolixys (previously … Continue Reading
Read Now
There’s Reason to Believe Tekmira Can Overcome this Safety Issue
Insights - There may be reason for investors to get comfortable with Tekmira's (TKMR) latest safety issue. Here's why.
Read Now
Some Relief for Investors: Zogenix Says New Painkiller as Early as 2015
Insights - Shares of biopharmaceutical company Zogenix, Inc. (ZGNX) are up 16% in trading on Wednesday after the company announced that a new, abuse-deterrent formulation of Zohydro … Continue Reading
Read Now
Why Agenus’ Rally on Brain Cancer Results May Be Short-Lived
Insights - Agenus (AGEN) reported on Tuesday updated results from an open-label, single-arm phase 2 study of Prophage, the company’s cancer vaccine, in glioblastoma multiforme. Patients treated with Prophage plus standard of care … Continue Reading
Read Now
No Surprise Here, Synageva is On Its Way to the FDA
Insights - Synageva BioPharma (GEVA) announced Monday after the close that the phase 3 ARISE trial of lead drug candidate sebelipase alfa successfully met its primary endpoint, and the company will … Continue Reading
Read Now